ALGS - Aligos Therapeutics, Inc.

6.13
-0.380   -6.199%

Share volume: 253,601
Last Updated: 04-23-2026
Pharmaceutical Products/Biological Products, Except Diagnostic Substances: 0.21%

PREVIOUS CLOSE
CHG
CHG%
$6.51
-0.38
-0.06%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
34%
Profitability 35%
Dept financing 27%
Liquidity 50%
Performance 30%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-5.84%
1 Month
-9.72%
3 Months
-26.94%
6 Months
-36.71%
1 Year
5.15%
2 Year
639.45%
Key data
Stock price
$6.13
P/E Ratio 
N/A
DAY RANGE
$5.97 - $6.53
EPS 
-$13.04
52 WEEK RANGE
$4.20 - $13.69
52 WEEK CHANGE
$12.48
MARKET CAP 
0.000
YIELD 
N/A
SHARES OUTSTANDING 
12.376 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-06-2025
BETA 
-0.14
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$988,395
AVERAGE 30 VOLUME 
$404,665
Company detail
CEO: Lawrence M. Blatt
Region: US
Website: www.aligos.com
Employees: 90
IPO year: 2020
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB)

Recent news